Financials

v3.7.0.1
CONSOLIDATED BALANCE SHEETS - USD ($)
Mar. 31, 2017
Dec. 31, 2016
Current Assets    
Cash $ 1,992,671 $ 892,814
Prepaid expenses 161,672 364,822
Short-term receivable 150,000 0
Total Current Assets 2,304,343 1,257,636
Long Term Receivable 0 150,000
Property and Equipment, Net 94,449 97,590
Deposits 2,751 2,751
Total Assets 2,401,543 1,507,977
Current Liabilities    
Interest payable 69,222 69,222
Accounts payable 220,700 225,725
Accrued liabilities 45,000 459,800
Notes payable, current portion 82,329 126,086
Short-term note payable, net of debt discount 0 970,240
Total Current Liabilities 417,251 1,851,073
Long-Term Liabilities    
Notes payable, net of current portion 87,814 103,742
Deferred rent 1,179 1,179
Total Long-Term Liabilities 88,993 404,921
Total Liabilities 506,244 1,955,994
Stockholders' Equity (Deficit)    
Preferred stock - $.001 par value: 500,000 shares authorized, 22,139 shares issued, 17,993 shares outstanding at March 31, 2017 (unaudited), no shares issued and outstanding at December 31, 2016 18 0
Common stock - $.001 par value: 49,500,000 shares authorized, 17,441,351 and 14,855,181 shares issued at March 31, 2017 (unaudited) and December 31, 2016, respectively, 17,441,351 and 14,855,181 shares outstanding at March 31, 2017 (unaudited) and December 31, 2016, respectively 17,442 14,855
Additional paid-in capital 30,477,753 25,898,054
Accumulated deficit (28,599,914) (26,360,926)
Total Stockholders' Equity (Deficit) 1,895,299 (448,017)
Total Liabilities and Stockholders' Equity (Deficit) $ 2,401,543 $ 1,507,977

Source

v3.7.0.1
UNAUDITED CONSOLIDATED STATEMENTS OF OPERATIONS - USD ($)
3 Months Ended
Mar. 31, 2017
Mar. 31, 2016
Unaudited Consolidated Statements Of Operations    
Revenues
Operating Expenses    
General and administrative 1,423,229 1,050,878
Sales and marketing 82,137 21,272
Research and development 335,440 143,183
Depreciation and amortization 6,221 1,963
Total Operating Expenses 1,847,027 1,217,296
Operating Loss (1,847,027) (1,217,296)
Other Expenses    
Interest expense 390,798 344,093
Total Other Expenses 390,798 344,093
Loss from Continuing Operations (2,237,825) (1,561,389)
Discontinued Operations    
Loss from discontinued operations 1,163 270,897
Total Loss from Discontinued Operations (1,163) (270,897)
Net Loss $ (2,238,988) $ (1,832,286)
Basic and diluted net loss per common share from continuing operations $ (.14) $ (0.14)
Basic and diluted net loss per common share from discontinued operations 0 (0.02)
Basic and diluted net loss per common share $ (.14) $ (0.16)
Weighted average outstanding shares used to compute basic net loss per share 16,271,075 11,624,202
Weighted average outstanding shares used to compute diluted net loss per share 16,271,075 11,624,202

Source

v3.7.0.1
UNAUDITED CONSOLIDATED STATEMENTS OF CASH FLOWS - USD ($)
3 Months Ended
Mar. 31, 2017
Mar. 31, 2016
Cash Flows from Operating Activities    
Net loss $ (2,238,988) $ (1,832,286)
Adjustments to reconcile net loss to net cash used in operating activities:    
Depreciation 6,221 2,028
Amortization of intangibles 0 142,142
Amortization of debt discount 31,772 246,086
Debt conversion expense 356,400 68,694
Stock based compensation 605,833 261,991
Straight-line rent adjustment 0 295
Non-cash directors fees 0 5,000
Adjustment of fair value of warrant modification 0 25,720
Changes in operating assets and liabilities, net of effects of acquisition:    
Accounts receivable 0 33,045
Prepaid expenses 203,150 14,217
Accounts payable (5,025) (67,497)
Interest payable 0 (3,671)
Accrued liabilities (414,800) 48,755
Net Cash Used in Operating Activities (1,455,437) (1,055,481)
Cash Flows from Investing Activities    
Expenditures for property and equipment (3,080) (3,213)
Net Cash Used in Investing Activities (3,080) (3,213)
Cash Flows from Financing Activities    
Principal payments under note payable obligation (59,686) (40,249)
Proceeds from issuance of common stock, net of offering costs 1,923,248 0
Proceeds from issuance of warrants, net of offering costs 694,812 0
Net Cash Provided by (Used in) Financing Activities 2,558,374 (40,249)
Net Increase/(Decrease) in Cash 1,099,857 (1,098,943)
Cash - Beginning of period 892,814 1,570,167
Cash - End of period 1,992,671 471,224
Supplementary Cash Flow Information    
Cash paid for interest 3,037 2,756
Non-cash investing and financing activities    
Financing agreement for insurance policy 44,701 0
Conversion of note and accrued interest to common stock 0 1,072,513
Conversion of short-term loan to common stock 126,720 0
Issuance of common stock for consideration of cancellation of warrants 208,000 0
Repayment of due from stockholder through forgone director fees 0 5,000
Issuance of warrants for conversion of notes 305,201 0
Stock issued for board fees 239,826 0
Issuance of stock for preferred stock conversion $ 411 $ 0

Source

Disclaimer

Medovex Corp. maintains this website as a service to the financial and internet communities. The site is intended to provide general information about the Company. It is not designed to be a source for making investment decisions. Medovex will make every reasonable effort to include accurate and current information on this website.

Except for the historical information contained herein, the information on the site may include forward-looking statements that involve risks and uncertainties that could cause actual results to differ materially from those projected. More complete information is contained in the company’s SEC filings.

Neither Medovex Corp nor any party involved in creating, producing or delivering this site shall be liable for any direct, incidental, consequential, indirect, or punitive damages arising out of the user’s access, use, or liability to use the Company’s website, or any errors or omissions in the content of the Medovex Corp website.

Terms of Use
General

Medovex Corp. (“the Company”) has made a reasonable effort to provide accurate and current information on this website.

It is important to note that nothing on our website constitutes or should be construed as investment advice. Date and information presented is not furnished in connection with any sale, offer of sale, solicitation or an offer to buy a security.

Solicited Policy

Neither Medovex nor any of its employees accept or consider unsolicited ideas regarding marketing, technologies or product names. The goal is to avoid any potential misunderstandings when Medovex’s products or marketing strategies might appear similar to ideas submitted to the Company.

No Offer or Advice

This website does not constitute an offer to sell or a solicitation of an offer to buy any security referenced on this website. Medovex’s management never represents that a security, product or service discussed here, are suitable for any particular investor. We do not guarantee the accuracy, completeness or timeliness. We strongly advise that all individuals be aware of the risks involved in every business and stock. You can help protect yourself by being an educated investor by closely examining Company documents filed with the Securities and Exchange Commission (SEC) as well as all other documents that have been published.

Limitation of Liability – SEC Rule 606

Use of this website is at the viewer’s own risk. Its content including but not limited to: any graphics, links or other terms are provided on an “as is” basis without warranties or representations of any kind. The Company expressly disclaims any liability for any errors or omissions in the content included in this website. All changes (should and when they may occur) are effective immediately upon posting to this website.

Archived and Forward Information

Any reports filed with the SEC may contain forward-looking statements that are made pursuant to the Safe Harbor provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements involve risks, some of which may be outside the Company’s control and may include economic, political and market fluctuations. Medovex undertakes no obligation to update or revise publicly any forward looking statement whether as a result of new information, future events or otherwise.

The Company strongly recommends readers carefully review all other documents and periodic reports filed by the Company with the SEC.

Medovex cannot and does not guarantee or warrant that files available for downloading (if any) through this site will be free of infection by software viruses or other harmful computer code, files or programs.